These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11641789)

  • 1. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
    Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
    Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
    Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub LB; Roth JA; Tanaka N
    Oncogene; 1999 Apr; 18(13):2189-99. PubMed ID: 10327065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer.
    Lee SH; Shin MS; Park WS; Kim SY; Kim HS; Han JY; Park GS; Dong SM; Pi JH; Kim CS; Kim SH; Lee JY; Yoo NJ
    Oncogene; 1999 Jun; 18(25):3754-60. PubMed ID: 10391683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma.
    Shin MS; Park WS; Kim SY; Kim HS; Kang SJ; Song KY; Park JY; Dong SM; Pi JH; Oh RR; Lee JY; Yoo NJ; Lee SH
    Am J Pathol; 1999 Jun; 154(6):1785-91. PubMed ID: 10362803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder.
    Lee SH; Shin MS; Park WS; Kim SY; Dong SM; Pi JH; Lee HK; Kim HS; Jang JJ; Kim CS; Kim SH; Lee JY; Yoo NJ
    Cancer Res; 1999 Jul; 59(13):3068-72. PubMed ID: 10397246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
    Wu WG; Soria JC; Wang L; Kemp BL; Mao L
    Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance related genes and p53 expression in human non small cell lung cancer.
    Galimberti S; Marchetti A; Buttitta F; Carnicelli V; Pellegrini S; Bevilacqua G; Petrini M
    Anticancer Res; 1998; 18(4C):2973-6. PubMed ID: 9713494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC).
    Komiya T; Hirashima T; Kikui M; Fukuoka M; Ohno A; Kawase I
    Anticancer Res; 1999; 19(5B):4315-9. PubMed ID: 10628393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer.
    Sunahara M; Shishikura T; Takahashi M; Todo S; Yamamoto N; Kimura H; Kato S; Ishioka C; Ikawa S; Ikawa Y; Nakagawara A
    Oncogene; 1999 Jun; 18(25):3761-5. PubMed ID: 10391684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation.
    Marchetti A; Doglioni C; Barbareschi M; Buttitta F; Pellegrini S; Bertacca G; Chella A; Merlo G; Angeletti CA; Dalla Palma P; Bevilacqua G
    Oncogene; 1996 Mar; 12(6):1319-24. PubMed ID: 8649834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of mutation types of p53 gene and possible carcinogenic factors in lung cancer].
    Gao ZQ; Gao Z; Zhang X
    Zhonghua Yu Fang Yi Xue Za Zhi; 1997 Mar; 31(2):88-91. PubMed ID: 9812619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo expression of soluble Fas and FAP-1: possible mechanisms of Fas resistance in human hepatoblastomas.
    Lee SH; Shin MS; Lee JY; Park WS; Kim SY; Jang JJ; Dong SM; Na EY; Kim CS; Kim SH; Yoo NJ
    J Pathol; 1999 Jun; 188(2):207-12. PubMed ID: 10398166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung.
    Kishimoto Y; Murakami Y; Shiraishi M; Hayashi K; Sekiya T
    Cancer Res; 1992 Sep; 52(17):4799-804. PubMed ID: 1324794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
    Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
    Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients.
    Boulay JL; Perruchoud AP; Reuter J; Bolliger C; Herrmann R; Rochlitz C
    Cancer Gene Ther; 2000 Sep; 7(9):1215-9. PubMed ID: 11023193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of p53 in non-small-cell lung cancer.
    Komiya T; Hirashima T; Kawase I
    Oncol Rep; 1999; 6(1):19-28. PubMed ID: 9864395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.